Clinical trials: No Disease
Liver Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
- Trial name
- NCT02013830
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 7 sites in Australia, Hong Kong and 2 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Gastroesophageal Reflux
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
This observational study aims to explore the effectiveness of hydrotalcite, marketed as Talcid, in alleviating acid-related symptoms that occur due to an acid rebound after discontinuing a non-/no-longer-indicated long-term…
- Trial name
- NCT07291700
- Testing
- Hydrotalcite (Talcid, BAYX002833)
- Where
- 2 sites in Germany
- Volunteers
- 167 people
- Sponsor
- Bayer
Asthma
Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment
The purpose of this study is to demonstrate substantial equivalence between two medical devices which measure nitric oxide in exhaled breath, NIOX MINO® and NIOX® in Symptomatic Asthmatic Adults and Children.
- Trial name
- eNOugh (NCT00388570)
- Testing
- The Aerocrine NIOX MINO® Airway Inflammation Monitor
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 151 people
- Sponsor
- Aerocrine AB
No Condition
CLAiR Pivotal Study
This is a multi-site, observational clinical study to validate the performance of the CLAiR AI software in identifying elevated atherosclerotic cardiovascular disease (ASCVD) risk from retinal (eye) images obtained from two…
- Trial name
- NCT06808334
- Testing
- CLAIR
- Where
- United States
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Toku Eyes Ltd
Chagas Disease
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
This is a study to compare the efficacy of oral posaconazole to placebo for the treatment of asymptomatic Chagas disease. The primary hypothesis of the study is that posaconazole 400 mg twice daily improves therapeutic response…
- Trial name
- STOP CHAGAS (NCT01377480)
- Testing
- Posaconazole, Benznidazole
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
This Phase 3 clinical study is designed to evaluate the safety, tolerability, and efficacy of two dose levels of Infergen (interferon alfacon-1, CIFN) plus Ribavirin administered daily for 48 weeks and no treatment in patients…
- Trial name
- NCT00086541
- Testing
- Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
- Volunteers
- 515 people
- Sponsor
- Bausch Health Americas, Inc.
no Specific Condition Targeted
Assessment of the Benefit of the Mobility Assistance System (SAM) on Transfer Independence for a Reimbursement Request
This is a randomized, cross-over, multi-center, intention-to-treat, open-label study to assess the impact of the SAM Ergonom light (SAM) device on independence when transferring from the supine to the sitting position at the edge…
- Trial name
- SAM-24 (NCT06698653)
- Testing
- SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process, Over bed pole hoist (control device)
- Where
- 3 sites in France
- Volunteers
- 54 people
- Sponsor
- WINNCARE
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Colo-rectal Cancer
Therascreen® KRAS RGQ PCR Kit
An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from patients with Colorectal Cancer (CRC) who have previously tested positive for the KRAS G12C mutation for…
- Trial name
- NCT05347745
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Acute Myelogenous Leukemia (AML)
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)
This is a study of MK-8242 alone and in combination with cytarabine in adult participants with refractory or recurrent acute myelogenous leukemia (AML). The study will have 2 Arms.
- Trial name
- NCT01451437
- Testing
- MK-8242
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
No Disease
A Study to Test the Repeatability and Reproducibility in Rod Intercept Time Within the AdaptDx Pro in Healthy Subjects With Normal Vision (FlashForward)
The purpose of this study is to test the repeatability and reproducibility in Rod Intercept (RI) time with two AdaptDx Pro devices in healthy subjects with normal vision.
- Trial name
- FlashForward (NCT07860905)
- Testing
- AdaptDx Pro
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AdaptDx, Inc.
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
The study will evaluate the safety and immunogenicity of the 2014-2015 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02222870
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Breast Cancer, Bone Metastases
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have…
- Trial name
- NCT01070485
- Testing
- Radium-223 chloride (BAY88-8223)
- Where
- 4 sites in Belgium, Norway and 1 more
- Volunteers
- 23 people
- Sponsor
- Bayer
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Leukemia, Neoplasms
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
The present trial will be performed according to an open design to determine the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group…
- Trial name
- NCT01971476
- Testing
- volasertib
- Where
- 5 sites in Belgium, Czechia and 3 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- NCT02100085
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Genexine, Inc.
Renal Impairment
An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the effect of impaired renal function on the PK of deferiprone and its 3-O-glucuronide metabolite following a single oral dose of 33mg/kg…
- Trial name
- NCT01770652
- Testing
- Deferiprone
- Where
- 2 sites in Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Sinus Node Disease
To Pace or Not to Pace in Sinus Node Disease
Optimal pacing strategy for patients with SND is still unknown, although several publications in the past years demonstrated a deleterious effect of ventricular pacing.
- Trial name
- OPTIMIST (NCT02485093)
- Testing
- Septal ventricular pacing, VIP
- Where
- France
- Volunteers
- 215 people
- Sponsor
- Abbott Medical Devices